| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laparoscopy | 61 | 2025 | 784 | 17.660 |
Why?
|
| Gastroesophageal Reflux | 27 | 2025 | 121 | 15.610 |
Why?
|
| Esophageal Achalasia | 29 | 2025 | 61 | 12.550 |
Why?
|
| Deglutition Disorders | 17 | 2025 | 126 | 10.180 |
Why?
|
| Myotomy | 23 | 2025 | 31 | 9.130 |
Why?
|
| Natural Orifice Endoscopic Surgery | 20 | 2025 | 41 | 8.370 |
Why?
|
| Fundoplication | 25 | 2025 | 73 | 8.130 |
Why?
|
| Hernia, Inguinal | 18 | 2024 | 75 | 7.020 |
Why?
|
| Herniorrhaphy | 21 | 2025 | 91 | 6.870 |
Why?
|
| Cholecystectomy, Laparoscopic | 13 | 2023 | 52 | 5.670 |
Why?
|
| Obesity, Morbid | 16 | 2024 | 248 | 5.630 |
Why?
|
| Gastric Bypass | 10 | 2024 | 114 | 5.560 |
Why?
|
| Quality of Life | 40 | 2025 | 1816 | 5.530 |
Why?
|
| Simulation Training | 11 | 2022 | 108 | 5.190 |
Why?
|
| Electric Impedance | 21 | 2025 | 117 | 5.140 |
Why?
|
| Treatment Outcome | 90 | 2025 | 9228 | 4.290 |
Why?
|
| Hernia, Hiatal | 9 | 2024 | 36 | 4.000 |
Why?
|
| Esophagoscopy | 17 | 2025 | 91 | 3.970 |
Why?
|
| Heller Myotomy | 6 | 2025 | 8 | 3.910 |
Why?
|
| Esophageal Motility Disorders | 8 | 2024 | 17 | 3.710 |
Why?
|
| Postoperative Complications | 26 | 2025 | 2603 | 3.520 |
Why?
|
| Retrospective Studies | 88 | 2025 | 10307 | 3.380 |
Why?
|
| Gastroplasty | 7 | 2024 | 27 | 3.230 |
Why?
|
| Pyloromyotomy | 7 | 2025 | 13 | 3.160 |
Why?
|
| Zenker Diverticulum | 7 | 2025 | 10 | 3.080 |
Why?
|
| Bariatric Surgery | 7 | 2025 | 207 | 3.020 |
Why?
|
| Barrett Esophagus | 7 | 2024 | 94 | 2.950 |
Why?
|
| Esophageal Sphincter, Lower | 15 | 2023 | 32 | 2.830 |
Why?
|
| Clinical Competence | 19 | 2022 | 858 | 2.820 |
Why?
|
| Suture Techniques | 8 | 2025 | 143 | 2.810 |
Why?
|
| Humans | 202 | 2025 | 95992 | 2.800 |
Why?
|
| Curriculum | 12 | 2022 | 616 | 2.790 |
Why?
|
| Surgeons | 9 | 2022 | 298 | 2.660 |
Why?
|
| Esophagogastric Junction | 7 | 2022 | 35 | 2.590 |
Why?
|
| Surgical Mesh | 12 | 2023 | 125 | 2.550 |
Why?
|
| Pain, Postoperative | 9 | 2021 | 277 | 2.400 |
Why?
|
| Middle Aged | 93 | 2025 | 28299 | 2.390 |
Why?
|
| Male | 114 | 2025 | 45792 | 2.280 |
Why?
|
| Endoscopy | 15 | 2024 | 374 | 2.170 |
Why?
|
| Internship and Residency | 9 | 2022 | 1134 | 2.130 |
Why?
|
| Aged | 71 | 2025 | 20927 | 2.120 |
Why?
|
| Female | 111 | 2025 | 49980 | 2.110 |
Why?
|
| Reoperation | 8 | 2025 | 712 | 2.000 |
Why?
|
| Stomach | 7 | 2023 | 116 | 1.920 |
Why?
|
| Education, Medical, Continuing | 5 | 2019 | 112 | 1.910 |
Why?
|
| Esophagus | 6 | 2024 | 113 | 1.900 |
Why?
|
| Adult | 71 | 2025 | 28636 | 1.850 |
Why?
|
| Weight Gain | 6 | 2019 | 129 | 1.850 |
Why?
|
| Endoscopy, Gastrointestinal | 9 | 2023 | 161 | 1.800 |
Why?
|
| Gastroparesis | 5 | 2025 | 16 | 1.760 |
Why?
|
| Esophageal Neoplasms | 7 | 2024 | 345 | 1.700 |
Why?
|
| Incisional Hernia | 6 | 2025 | 19 | 1.600 |
Why?
|
| Adenocarcinoma | 11 | 2024 | 1191 | 1.580 |
Why?
|
| Recurrence | 17 | 2025 | 1231 | 1.550 |
Why?
|
| Surgical Stomas | 5 | 2018 | 22 | 1.540 |
Why?
|
| Operating Rooms | 6 | 2022 | 138 | 1.500 |
Why?
|
| Gastrectomy | 3 | 2024 | 70 | 1.500 |
Why?
|
| Hernia, Abdominal | 4 | 2021 | 14 | 1.470 |
Why?
|
| Prospective Studies | 25 | 2025 | 4690 | 1.460 |
Why?
|
| General Surgery | 4 | 2020 | 255 | 1.420 |
Why?
|
| Weight Loss | 10 | 2024 | 240 | 1.420 |
Why?
|
| Esophagitis, Peptic | 2 | 2022 | 10 | 1.390 |
Why?
|
| Manometry | 5 | 2025 | 45 | 1.350 |
Why?
|
| Choledocholithiasis | 2 | 2023 | 14 | 1.340 |
Why?
|
| Esophagectomy | 4 | 2024 | 92 | 1.290 |
Why?
|
| Patient Safety | 5 | 2019 | 225 | 1.250 |
Why?
|
| Endoscopy, Digestive System | 3 | 2021 | 72 | 1.190 |
Why?
|
| Hospital Costs | 6 | 2016 | 117 | 1.160 |
Why?
|
| Intraoperative Complications | 3 | 2022 | 197 | 1.120 |
Why?
|
| Dilatation | 2 | 2025 | 48 | 1.100 |
Why?
|
| Education, Medical, Graduate | 4 | 2019 | 438 | 1.040 |
Why?
|
| Hospital Charges | 2 | 2020 | 32 | 1.030 |
Why?
|
| Hernia, Ventral | 4 | 2025 | 28 | 1.020 |
Why?
|
| Disposable Equipment | 3 | 2016 | 23 | 1.020 |
Why?
|
| Duodenum | 3 | 2024 | 112 | 1.010 |
Why?
|
| Jejunum | 3 | 2016 | 80 | 1.010 |
Why?
|
| Cholecystitis | 2 | 2020 | 17 | 1.010 |
Why?
|
| Computer Simulation | 7 | 2022 | 1158 | 1.000 |
Why?
|
| Obesity | 10 | 2024 | 1029 | 0.990 |
Why?
|
| Cholecystectomy | 3 | 2022 | 26 | 0.970 |
Why?
|
| Physicians | 4 | 2024 | 707 | 0.950 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 43 | 0.930 |
Why?
|
| Length of Stay | 11 | 2024 | 835 | 0.930 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 234 | 0.910 |
Why?
|
| Cysts | 3 | 2014 | 104 | 0.900 |
Why?
|
| Thrombelastography | 1 | 2025 | 48 | 0.900 |
Why?
|
| Monitoring, Intraoperative | 2 | 2025 | 116 | 0.890 |
Why?
|
| Pancreatic Neoplasms | 14 | 2011 | 725 | 0.860 |
Why?
|
| Delphi Technique | 2 | 2024 | 136 | 0.850 |
Why?
|
| Preoperative Care | 8 | 2025 | 419 | 0.840 |
Why?
|
| Follow-Up Studies | 17 | 2022 | 3922 | 0.830 |
Why?
|
| Operative Time | 10 | 2025 | 168 | 0.810 |
Why?
|
| Laparotomy | 3 | 2019 | 63 | 0.810 |
Why?
|
| Sutures | 2 | 2022 | 59 | 0.790 |
Why?
|
| Esophagitis | 1 | 2023 | 40 | 0.790 |
Why?
|
| Hernia, Umbilical | 2 | 2021 | 13 | 0.790 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 171 | 0.760 |
Why?
|
| Common Bile Duct | 2 | 2023 | 19 | 0.740 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2020 | 28 | 0.730 |
Why?
|
| Hernia | 3 | 2022 | 23 | 0.720 |
Why?
|
| Biological Products | 2 | 2023 | 179 | 0.720 |
Why?
|
| Emotions | 1 | 2025 | 377 | 0.700 |
Why?
|
| Foreign Bodies | 1 | 2022 | 66 | 0.700 |
Why?
|
| Specialties, Surgical | 3 | 2017 | 77 | 0.700 |
Why?
|
| Risk Assessment | 7 | 2025 | 2498 | 0.690 |
Why?
|
| Virtual Reality | 1 | 2022 | 39 | 0.690 |
Why?
|
| Safety | 1 | 2021 | 147 | 0.680 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 7224 | 0.670 |
Why?
|
| Swine | 6 | 2025 | 607 | 0.670 |
Why?
|
| Abdominal Wall | 2 | 2020 | 32 | 0.660 |
Why?
|
| Gastroscopy | 3 | 2024 | 25 | 0.660 |
Why?
|
| Esophagoplasty | 1 | 2020 | 9 | 0.660 |
Why?
|
| Body Mass Index | 7 | 2024 | 816 | 0.660 |
Why?
|
| Stents | 3 | 2022 | 422 | 0.660 |
Why?
|
| Insufflation | 1 | 2020 | 10 | 0.660 |
Why?
|
| Cohort Studies | 12 | 2023 | 3115 | 0.650 |
Why?
|
| Jejunostomy | 2 | 2018 | 13 | 0.640 |
Why?
|
| Cholelithiasis | 1 | 2020 | 36 | 0.630 |
Why?
|
| Rectus Abdominis | 2 | 2017 | 41 | 0.630 |
Why?
|
| Safety Management | 2 | 2018 | 58 | 0.620 |
Why?
|
| Decision Making | 1 | 2025 | 695 | 0.620 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 683 | 0.610 |
Why?
|
| Gastric Mucosa | 2 | 2020 | 70 | 0.610 |
Why?
|
| Surveys and Questionnaires | 10 | 2024 | 2860 | 0.610 |
Why?
|
| Teaching | 1 | 2020 | 154 | 0.600 |
Why?
|
| Cardia | 1 | 2019 | 5 | 0.590 |
Why?
|
| Feasibility Studies | 8 | 2025 | 819 | 0.590 |
Why?
|
| Fires | 1 | 2019 | 22 | 0.580 |
Why?
|
| Hypoglycemia | 1 | 2019 | 112 | 0.580 |
Why?
|
| Databases, Factual | 8 | 2021 | 1014 | 0.580 |
Why?
|
| Perception | 1 | 2020 | 185 | 0.580 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 40 | 0.570 |
Why?
|
| Pancreaticoduodenectomy | 5 | 2018 | 92 | 0.570 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 110 | 0.560 |
Why?
|
| Time Factors | 11 | 2021 | 5593 | 0.560 |
Why?
|
| Pancreatectomy | 5 | 2011 | 168 | 0.560 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 153 | 0.560 |
Why?
|
| Pylorus | 5 | 2021 | 15 | 0.540 |
Why?
|
| Parathyroid Diseases | 2 | 2008 | 9 | 0.540 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 197 | 0.540 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2016 | 287 | 0.540 |
Why?
|
| Chronic Pain | 1 | 2020 | 186 | 0.530 |
Why?
|
| Gastric Emptying | 4 | 2025 | 26 | 0.530 |
Why?
|
| Cell Cycle | 5 | 2010 | 516 | 0.530 |
Why?
|
| Gastrostomy | 1 | 2018 | 69 | 0.530 |
Why?
|
| Phenotype | 1 | 2024 | 2575 | 0.520 |
Why?
|
| Prostatic Hyperplasia | 1 | 2018 | 97 | 0.520 |
Why?
|
| Stomach Neoplasms | 2 | 2020 | 310 | 0.520 |
Why?
|
| Postoperative Care | 2 | 2020 | 239 | 0.510 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 43 | 0.510 |
Why?
|
| Disease Progression | 6 | 2024 | 1561 | 0.510 |
Why?
|
| Thyroid Diseases | 2 | 2008 | 106 | 0.510 |
Why?
|
| Dexamethasone | 1 | 2018 | 350 | 0.500 |
Why?
|
| Laparoscopes | 1 | 2016 | 15 | 0.500 |
Why?
|
| Muscular Atrophy | 1 | 2017 | 48 | 0.500 |
Why?
|
| Referral and Consultation | 1 | 2020 | 387 | 0.500 |
Why?
|
| Patient Readmission | 5 | 2025 | 413 | 0.500 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 476 | 0.490 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 484 | 0.490 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 382 | 0.480 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 12 | 0.480 |
Why?
|
| Vascular Surgical Procedures | 3 | 2015 | 152 | 0.470 |
Why?
|
| Prostatectomy | 1 | 2019 | 480 | 0.470 |
Why?
|
| Goals | 1 | 2016 | 68 | 0.470 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 286 | 0.470 |
Why?
|
| Checklist | 1 | 2016 | 73 | 0.470 |
Why?
|
| Medical Errors | 1 | 2016 | 119 | 0.460 |
Why?
|
| Gastroenterology | 1 | 2017 | 157 | 0.460 |
Why?
|
| Patient Outcome Assessment | 2 | 2019 | 87 | 0.460 |
Why?
|
| Proton Pump Inhibitors | 3 | 2023 | 34 | 0.450 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2014 | 119 | 0.450 |
Why?
|
| Blood Vessels | 2 | 2015 | 91 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 570 | 0.450 |
Why?
|
| Hemostasis, Surgical | 1 | 2015 | 25 | 0.450 |
Why?
|
| Ultrasonics | 1 | 2015 | 38 | 0.450 |
Why?
|
| Cell Proliferation | 6 | 2010 | 1753 | 0.440 |
Why?
|
| Catheter Ablation | 4 | 2011 | 365 | 0.430 |
Why?
|
| Registries | 3 | 2022 | 998 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2022 | 246 | 0.430 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 45 | 0.420 |
Why?
|
| Splenic Diseases | 1 | 2014 | 14 | 0.420 |
Why?
|
| Arteries | 2 | 2012 | 181 | 0.420 |
Why?
|
| Treatment Failure | 2 | 2025 | 297 | 0.410 |
Why?
|
| Apigenin | 3 | 2009 | 8 | 0.410 |
Why?
|
| Gallbladder Diseases | 1 | 2013 | 21 | 0.400 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 2042 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 2777 | 0.380 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2012 | 10 | 0.380 |
Why?
|
| Biliary Dyskinesia | 1 | 2012 | 3 | 0.380 |
Why?
|
| Bile Ducts | 3 | 2022 | 61 | 0.380 |
Why?
|
| Gallstones | 1 | 2012 | 21 | 0.380 |
Why?
|
| Depsipeptides | 3 | 2010 | 32 | 0.370 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 358 | 0.370 |
Why?
|
| Ischemic Preconditioning | 1 | 2012 | 37 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 2495 | 0.370 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 500 | 0.360 |
Why?
|
| Manikins | 1 | 2011 | 45 | 0.350 |
Why?
|
| Competency-Based Education | 1 | 2011 | 38 | 0.350 |
Why?
|
| Models, Anatomic | 1 | 2011 | 93 | 0.350 |
Why?
|
| Pain Measurement | 3 | 2020 | 378 | 0.350 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 48 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 2474 | 0.340 |
Why?
|
| Patient Satisfaction | 3 | 2024 | 514 | 0.340 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 229 | 0.340 |
Why?
|
| Postoperative Period | 3 | 2016 | 318 | 0.330 |
Why?
|
| Risk Factors | 8 | 2024 | 5992 | 0.320 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 25 | 0.320 |
Why?
|
| Consensus | 2 | 2024 | 372 | 0.320 |
Why?
|
| Esophageal Sphincter, Upper | 2 | 2020 | 5 | 0.320 |
Why?
|
| Patient Discharge | 2 | 2025 | 363 | 0.310 |
Why?
|
| Sex Factors | 3 | 2024 | 1130 | 0.290 |
Why?
|
| Video Recording | 3 | 2019 | 215 | 0.280 |
Why?
|
| Peritoneum | 2 | 2020 | 55 | 0.280 |
Why?
|
| Incidence | 5 | 2017 | 1723 | 0.280 |
Why?
|
| G2 Phase | 2 | 2009 | 33 | 0.270 |
Why?
|
| Single-Blind Method | 3 | 2019 | 162 | 0.270 |
Why?
|
| Recovery of Function | 3 | 2019 | 348 | 0.260 |
Why?
|
| Mitosis | 2 | 2009 | 152 | 0.260 |
Why?
|
| Illinois | 4 | 2016 | 530 | 0.260 |
Why?
|
| Peritoneal Dialysis | 2 | 2017 | 31 | 0.250 |
Why?
|
| Activities of Daily Living | 2 | 2020 | 216 | 0.250 |
Why?
|
| Young Adult | 6 | 2019 | 7034 | 0.250 |
Why?
|
| Catheters, Indwelling | 2 | 2017 | 113 | 0.240 |
Why?
|
| Quality Improvement | 2 | 2021 | 502 | 0.240 |
Why?
|
| Task Performance and Analysis | 2 | 2016 | 92 | 0.240 |
Why?
|
| Program Evaluation | 2 | 2019 | 323 | 0.240 |
Why?
|
| Intussusception | 1 | 2006 | 16 | 0.240 |
Why?
|
| Video-Assisted Surgery | 1 | 2006 | 7 | 0.240 |
Why?
|
| Stomach Diseases | 1 | 2006 | 19 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 890 | 0.240 |
Why?
|
| Pressure | 2 | 2018 | 175 | 0.240 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 26 | 0.240 |
Why?
|
| Mesentery | 1 | 2005 | 47 | 0.230 |
Why?
|
| Current Procedural Terminology | 1 | 2025 | 15 | 0.230 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2025 | 32 | 0.230 |
Why?
|
| von Willebrand Factor | 1 | 2025 | 40 | 0.230 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2006 | 57 | 0.230 |
Why?
|
| Robotic Surgical Procedures | 2 | 2022 | 367 | 0.230 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2025 | 46 | 0.230 |
Why?
|
| Educational Measurement | 3 | 2017 | 246 | 0.220 |
Why?
|
| Ischemia | 2 | 2011 | 256 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 905 | 0.220 |
Why?
|
| Thyroidectomy | 1 | 2006 | 173 | 0.220 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2025 | 33 | 0.220 |
Why?
|
| Equipment Contamination | 1 | 2025 | 29 | 0.220 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 1766 | 0.220 |
Why?
|
| Prognosis | 3 | 2020 | 3993 | 0.220 |
Why?
|
| Tracheostomy | 1 | 2025 | 46 | 0.220 |
Why?
|
| Equipment Design | 2 | 2016 | 435 | 0.220 |
Why?
|
| Diverticulum, Esophageal | 1 | 2024 | 6 | 0.210 |
Why?
|
| Physical Examination | 1 | 2025 | 153 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2025 | 206 | 0.210 |
Why?
|
| Animals | 9 | 2025 | 28901 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 157 | 0.200 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2023 | 70 | 0.200 |
Why?
|
| Anastomosis, Surgical | 3 | 2012 | 284 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 179 | 0.190 |
Why?
|
| Comorbidity | 3 | 2024 | 1017 | 0.190 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2022 | 9 | 0.190 |
Why?
|
| Magnetic Phenomena | 1 | 2022 | 4 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 432 | 0.190 |
Why?
|
| Bile Duct Diseases | 1 | 2022 | 23 | 0.190 |
Why?
|
| Internationality | 2 | 2020 | 77 | 0.190 |
Why?
|
| Vitamin D | 2 | 2015 | 273 | 0.180 |
Why?
|
| Abdominal Injuries | 1 | 2022 | 52 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1982 | 0.180 |
Why?
|
| United States | 9 | 2024 | 7785 | 0.180 |
Why?
|
| Self Concept | 2 | 2019 | 137 | 0.180 |
Why?
|
| Appendicitis | 1 | 2002 | 66 | 0.180 |
Why?
|
| Thyroid Neoplasms | 1 | 2006 | 443 | 0.170 |
Why?
|
| Esophageal Mucosa | 1 | 2020 | 4 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2022 | 196 | 0.160 |
Why?
|
| Age Factors | 3 | 2015 | 1959 | 0.160 |
Why?
|
| Intestine, Small | 2 | 2018 | 310 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 71 | 0.160 |
Why?
|
| Dumping Syndrome | 1 | 2019 | 5 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2022 | 263 | 0.160 |
Why?
|
| Wound Closure Techniques | 1 | 2019 | 15 | 0.150 |
Why?
|
| Device Removal | 1 | 2021 | 169 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2024 | 456 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 164 | 0.150 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 192 | 0.150 |
Why?
|
| Catheterization | 2 | 2017 | 237 | 0.150 |
Why?
|
| Cell Cycle Proteins | 4 | 2010 | 412 | 0.140 |
Why?
|
| Urinary Retention | 1 | 2018 | 46 | 0.140 |
Why?
|
| Hospitals, University | 2 | 2016 | 199 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1018 | 0.140 |
Why?
|
| Biomarkers | 1 | 2025 | 1931 | 0.140 |
Why?
|
| Adolescent | 5 | 2019 | 9878 | 0.140 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 38 | 0.140 |
Why?
|
| Quality Control | 1 | 2018 | 125 | 0.140 |
Why?
|
| Disease Management | 1 | 2020 | 363 | 0.140 |
Why?
|
| Suction | 2 | 2008 | 38 | 0.130 |
Why?
|
| Visual Analog Scale | 1 | 2017 | 18 | 0.130 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2007 | 121 | 0.130 |
Why?
|
| Crowdsourcing | 1 | 2017 | 12 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 123 | 0.130 |
Why?
|
| Regional Medical Programs | 1 | 2016 | 5 | 0.130 |
Why?
|
| Clinical Audit | 1 | 2016 | 9 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 56 | 0.130 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2016 | 26 | 0.120 |
Why?
|
| Atrophy | 1 | 2017 | 131 | 0.120 |
Why?
|
| Hypotension | 1 | 2017 | 76 | 0.120 |
Why?
|
| Mesenteric Veins | 2 | 2007 | 36 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2022 | 2611 | 0.120 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 790 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2018 | 369 | 0.120 |
Why?
|
| Omentum | 1 | 2016 | 68 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2020 | 391 | 0.120 |
Why?
|
| World Health Organization | 1 | 2016 | 122 | 0.120 |
Why?
|
| Cell Line, Tumor | 8 | 2010 | 2776 | 0.120 |
Why?
|
| Japan | 1 | 2016 | 313 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2007 | 239 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 1966 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2016 | 104 | 0.120 |
Why?
|
| Antineoplastic Agents | 4 | 2010 | 2385 | 0.120 |
Why?
|
| Appendectomy | 1 | 2015 | 38 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 506 | 0.120 |
Why?
|
| Constriction, Pathologic | 3 | 2012 | 219 | 0.120 |
Why?
|
| Iliac Vein | 2 | 2006 | 32 | 0.110 |
Why?
|
| Logistic Models | 4 | 2015 | 1273 | 0.110 |
Why?
|
| Cost Savings | 1 | 2015 | 71 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2015 | 63 | 0.110 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cost Control | 1 | 2015 | 45 | 0.110 |
Why?
|
| Caloric Restriction | 1 | 2015 | 15 | 0.110 |
Why?
|
| Regional Health Planning | 1 | 2014 | 13 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 231 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 107 | 0.110 |
Why?
|
| Algorithms | 3 | 2018 | 2018 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 40 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2015 | 35 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 365 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1329 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 99 | 0.110 |
Why?
|
| Hospitalization | 1 | 2020 | 946 | 0.110 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2014 | 8 | 0.110 |
Why?
|
| Palliative Care | 2 | 2007 | 271 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 386 | 0.110 |
Why?
|
| Image-Guided Biopsy | 1 | 2014 | 82 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2014 | 85 | 0.100 |
Why?
|
| Subcutaneous Emphysema | 1 | 2013 | 8 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 51 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 189 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2014 | 71 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2017 | 554 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 133 | 0.100 |
Why?
|
| Drainage | 1 | 2014 | 172 | 0.100 |
Why?
|
| Pancreas | 2 | 2005 | 263 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2008 | 1347 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 506 | 0.100 |
Why?
|
| Lymphoma | 1 | 2014 | 253 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1962 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 517 | 0.090 |
Why?
|
| Ligation | 1 | 2012 | 54 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2016 | 373 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 81 | 0.090 |
Why?
|
| Celiac Artery | 1 | 2012 | 25 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 463 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 403 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2012 | 105 | 0.090 |
Why?
|
| Syndrome | 1 | 2012 | 450 | 0.090 |
Why?
|
| Exercise | 1 | 2015 | 355 | 0.090 |
Why?
|
| United Kingdom | 2 | 2022 | 192 | 0.090 |
Why?
|
| Patient Simulation | 1 | 2011 | 51 | 0.090 |
Why?
|
| Biological Specimen Banks | 2 | 2022 | 72 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 79 | 0.090 |
Why?
|
| Analgesics | 1 | 2012 | 132 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 315 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2010 | 1156 | 0.080 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 109 | 0.080 |
Why?
|
| Students, Medical | 1 | 2016 | 455 | 0.080 |
Why?
|
| Cyclin A | 2 | 2010 | 28 | 0.080 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 59 | 0.080 |
Why?
|
| Angioplasty | 3 | 2007 | 69 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 126 | 0.080 |
Why?
|
| Cucumaria | 1 | 2010 | 1 | 0.080 |
Why?
|
| Complex Mixtures | 1 | 2010 | 6 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2010 | 526 | 0.080 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2007 | 17 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2011 | 178 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1464 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 212 | 0.080 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2009 | 7 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2010 | 155 | 0.080 |
Why?
|
| Esophageal pH Monitoring | 1 | 2009 | 12 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2009 | 796 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1618 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2009 | 725 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 201 | 0.070 |
Why?
|
| Intestinal Obstruction | 2 | 2011 | 94 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2011 | 747 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2009 | 216 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 287 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 135 | 0.070 |
Why?
|
| Probability | 2 | 2009 | 365 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 279 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2007 | 50 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2007 | 58 | 0.060 |
Why?
|
| Cyclin B | 1 | 2006 | 17 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2008 | 228 | 0.060 |
Why?
|
| Stilbenes | 1 | 2007 | 26 | 0.060 |
Why?
|
| cdc25 Phosphatases | 1 | 2006 | 19 | 0.060 |
Why?
|
| Hyperparathyroidism | 1 | 2007 | 65 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 47 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 271 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 1819 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 169 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 161 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 40 | 0.060 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 132 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 133 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 272 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 16 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2011 | 1069 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 644 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 100 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 270 | 0.060 |
Why?
|
| Aerosols | 1 | 2025 | 48 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 85 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 223 | 0.050 |
Why?
|
| Markov Chains | 1 | 2024 | 137 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2025 | 83 | 0.050 |
Why?
|
| Advance Directives | 1 | 2004 | 64 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2024 | 99 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2007 | 1541 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 62 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 224 | 0.050 |
Why?
|
| Acute Disease | 1 | 2005 | 859 | 0.050 |
Why?
|
| Thrombosis | 1 | 2006 | 326 | 0.050 |
Why?
|
| Cell Survival | 1 | 2006 | 1029 | 0.050 |
Why?
|
| Intestinal Diseases | 1 | 2004 | 85 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 261 | 0.050 |
Why?
|
| Child | 1 | 2014 | 7621 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 121 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 983 | 0.050 |
Why?
|
| Judgment | 1 | 2022 | 70 | 0.040 |
Why?
|
| Cell Line | 1 | 2006 | 2536 | 0.040 |
Why?
|
| Oregon | 2 | 2011 | 27 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 478 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 233 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 514 | 0.040 |
Why?
|
| Compliance | 1 | 2018 | 21 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 636 | 0.040 |
Why?
|
| Certification | 1 | 1999 | 66 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2042 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2534 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2017 | 48 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 3155 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1195 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 32 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 89 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 107 | 0.030 |
Why?
|
| Documentation | 1 | 2017 | 103 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 129 | 0.030 |
Why?
|
| Patient Selection | 2 | 2011 | 708 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 133 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 438 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 351 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 147 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 1998 | 485 | 0.030 |
Why?
|
| Models, Economic | 1 | 2015 | 62 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 936 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 175 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 49 | 0.030 |
Why?
|
| Cell Division | 2 | 2007 | 701 | 0.030 |
Why?
|
| Apoptosis | 2 | 2010 | 1756 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2017 | 926 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1792 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1267 | 0.020 |
Why?
|
| Pancreatic Fistula | 1 | 2011 | 17 | 0.020 |
Why?
|
| Ileus | 1 | 2011 | 14 | 0.020 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 23 | 0.020 |
Why?
|
| Hospital Departments | 1 | 2010 | 14 | 0.020 |
Why?
|
| Annexins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Deep Sedation | 1 | 2010 | 19 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2011 | 94 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 61 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 164 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 126 | 0.020 |
Why?
|
| Cyclin E | 1 | 2010 | 28 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 83 | 0.020 |
Why?
|
| Spleen | 1 | 2011 | 419 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 33 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 85 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 79 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2010 | 128 | 0.020 |
Why?
|
| S Phase | 1 | 2009 | 64 | 0.020 |
Why?
|
| Geminin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Leupeptins | 1 | 2008 | 22 | 0.020 |
Why?
|
| Neoplasms | 1 | 2004 | 3242 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 4155 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2008 | 54 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 317 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 237 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 112 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 2 | 1999 | 76 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 509 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 245 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 367 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2885 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 909 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1741 | 0.020 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2007 | 33 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 1978 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2006 | 42 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 426 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 12 | 0.010 |
Why?
|
| Butadienes | 1 | 2005 | 34 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 35 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 996 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 103 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 908 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 84 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 172 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 562 | 0.010 |
Why?
|
| Nitriles | 1 | 2005 | 157 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 701 | 0.010 |
Why?
|
| Arizona | 1 | 2004 | 10 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2007 | 740 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 436 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2004 | 98 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 750 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 2004 | 53 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 337 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2088 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1191 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 258 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2928 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1998 | 67 | 0.010 |
Why?
|
| California | 1 | 1998 | 161 | 0.010 |
Why?
|
| Surgery Department, Hospital | 1 | 1998 | 43 | 0.010 |
Why?
|
| Emergencies | 1 | 1998 | 123 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1319 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 1998 | 155 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1998 | 721 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 252 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 3581 | 0.010 |
Why?
|